Integrated acidity and rabeprazole pharmacology
Integrated gastric and oesophageal acidity can be calculated from measurements of gastric and oesophageal pH and used to quantify gastric and oesophageal acidity over time. Rabeprazole is a new proton pump inhibitor that is effective in treating gastro-oesophageal reflux disease (GERD).<section x...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Gardner, J. D. [verfasserIn] Perdomo, C. [verfasserIn] Sloan, S. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
Oxford UK: Blackwell Science Ltd. ; 2002 |
|---|
| Umfang: |
Online-Ressource |
|---|
| Reproduktion: |
2002 ; Blackwell Publishing Journal Backfiles 1879-2005 |
|---|---|
| Übergeordnetes Werk: |
In: Alimentary pharmacology & therapeutics - Oxford : Blackwell Science, 1987, 16(2002), 3, Seite 0 |
| Übergeordnetes Werk: |
volume:16 ; year:2002 ; number:3 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1046/j.1365-2036.2002.01158.x |
|---|
| Katalog-ID: |
NLEJ242206190 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ242206190 | ||
| 003 | DE-627 | ||
| 005 | 20230506180922.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 120427s2002 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1046/j.1365-2036.2002.01158.x |2 doi | |
| 035 | |a (DE-627)NLEJ242206190 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 100 | 1 | |a Gardner, J. D. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Integrated acidity and rabeprazole pharmacology |
| 264 | 1 | |a Oxford UK |b Blackwell Science Ltd. |c 2002 | |
| 300 | |a Online-Ressource | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Integrated gastric and oesophageal acidity can be calculated from measurements of gastric and oesophageal pH and used to quantify gastric and oesophageal acidity over time. Rabeprazole is a new proton pump inhibitor that is effective in treating gastro-oesophageal reflux disease (GERD).<section xml:id="abs1-2"><title type="main">Aim:To use measurement of integrated gastric and oesophageal acidity to determine the onset, duration and overall effect of rabeprazole in subjects with GERD.<section xml:id="abs1-3"><title type="main">Methods:Subjects with GERD were required to have oesophageal pH ≤ 4 for at least 10% of a 24-h recording. Effects of 20 mg rabeprazole on 24-h gastric and oesophageal pH were measured on days 1 and 7 of dosing. Integrated gastric and oesophageal acidity were calculated from time-weighted average hydrogen ion concentrations at each second of the 24-h record.<section xml:id="abs1-4"><title type="main">Results:At steady-state, 20 mg rabeprazole inhibited gastric acidity by 89% and oesophageal acidity by 95%. The first dose of rabeprazole inhibited gastric and oesophageal acidity by at least 70% of the steady-state effect. Oesophageal acidity could be divided into monophasic and biphasic patterns, and rabeprazole had different effects on oesophageal and gastric acidity in these two GERD subpopulations. The onset of action of the first dose of rabeprazole on gastric acidity was 4 h and on oesophageal acidity was 4 h in monophasic subjects and 7 h in biphasic subjects. Integrated acidity was more sensitive than time pH ≤ 4 in measuring the inhibitory actions of rabeprazole.<section xml:id="abs1-5"><title type="main">Conclusions:Integrated gastric and oesophageal acidity are quantitative measurements that provide useful and novel information regarding the pathophysiology of GERD as well as the impact of antisecretory agents such as rabeprazole. | ||
| 533 | |d 2002 |f Blackwell Publishing Journal Backfiles 1879-2005 |7 |2002|||||||||| | ||
| 700 | 1 | |a Perdomo, C. |e verfasserin |4 aut | |
| 700 | 1 | |a Sloan, S. |e verfasserin |4 aut | |
| 700 | 1 | |a Hahne, W. F. |4 oth | |
| 700 | 1 | |a Barth, J. A. |4 oth | |
| 700 | 1 | |a Rodriguez-Stanley, S. |4 oth | |
| 700 | 1 | |a Robinson, M. |4 oth | |
| 773 | 0 | 8 | |i In |t Alimentary pharmacology & therapeutics |d Oxford : Blackwell Science, 1987 |g 16(2002), 3, Seite 0 |h Online-Ressource |w (DE-627)NLEJ243926529 |w (DE-600)2003094-0 |x 1365-2036 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2002 |g number:3 |g pages:0 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1046/j.1365-2036.2002.01158.x |q text/html |x Verlag |z Deutschlandweit zugänglich |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-DJB | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2002 |e 3 |h 0 | ||
| author_variant |
j d g jd jdg c p cp s s ss |
|---|---|
| matchkey_str |
article:13652036:2002----::nertdcdtadaerzl |
| hierarchy_sort_str |
2002 |
| publishDate |
2002 |
| allfields |
10.1046/j.1365-2036.2002.01158.x doi (DE-627)NLEJ242206190 DE-627 ger DE-627 rakwb Gardner, J. D. verfasserin aut Integrated acidity and rabeprazole pharmacology Oxford UK Blackwell Science Ltd. 2002 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Integrated gastric and oesophageal acidity can be calculated from measurements of gastric and oesophageal pH and used to quantify gastric and oesophageal acidity over time. Rabeprazole is a new proton pump inhibitor that is effective in treating gastro-oesophageal reflux disease (GERD).<section xml:id="abs1-2"><title type="main">Aim:To use measurement of integrated gastric and oesophageal acidity to determine the onset, duration and overall effect of rabeprazole in subjects with GERD.<section xml:id="abs1-3"><title type="main">Methods:Subjects with GERD were required to have oesophageal pH ≤ 4 for at least 10% of a 24-h recording. Effects of 20 mg rabeprazole on 24-h gastric and oesophageal pH were measured on days 1 and 7 of dosing. Integrated gastric and oesophageal acidity were calculated from time-weighted average hydrogen ion concentrations at each second of the 24-h record.<section xml:id="abs1-4"><title type="main">Results:At steady-state, 20 mg rabeprazole inhibited gastric acidity by 89% and oesophageal acidity by 95%. The first dose of rabeprazole inhibited gastric and oesophageal acidity by at least 70% of the steady-state effect. Oesophageal acidity could be divided into monophasic and biphasic patterns, and rabeprazole had different effects on oesophageal and gastric acidity in these two GERD subpopulations. The onset of action of the first dose of rabeprazole on gastric acidity was 4 h and on oesophageal acidity was 4 h in monophasic subjects and 7 h in biphasic subjects. Integrated acidity was more sensitive than time pH ≤ 4 in measuring the inhibitory actions of rabeprazole.<section xml:id="abs1-5"><title type="main">Conclusions:Integrated gastric and oesophageal acidity are quantitative measurements that provide useful and novel information regarding the pathophysiology of GERD as well as the impact of antisecretory agents such as rabeprazole. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| Perdomo, C. verfasserin aut Sloan, S. verfasserin aut Hahne, W. F. oth Barth, J. A. oth Rodriguez-Stanley, S. oth Robinson, M. oth In Alimentary pharmacology & therapeutics Oxford : Blackwell Science, 1987 16(2002), 3, Seite 0 Online-Ressource (DE-627)NLEJ243926529 (DE-600)2003094-0 1365-2036 nnns volume:16 year:2002 number:3 pages:0 http://dx.doi.org/10.1046/j.1365-2036.2002.01158.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 16 2002 3 0 |
| spelling |
10.1046/j.1365-2036.2002.01158.x doi (DE-627)NLEJ242206190 DE-627 ger DE-627 rakwb Gardner, J. D. verfasserin aut Integrated acidity and rabeprazole pharmacology Oxford UK Blackwell Science Ltd. 2002 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Integrated gastric and oesophageal acidity can be calculated from measurements of gastric and oesophageal pH and used to quantify gastric and oesophageal acidity over time. Rabeprazole is a new proton pump inhibitor that is effective in treating gastro-oesophageal reflux disease (GERD).<section xml:id="abs1-2"><title type="main">Aim:To use measurement of integrated gastric and oesophageal acidity to determine the onset, duration and overall effect of rabeprazole in subjects with GERD.<section xml:id="abs1-3"><title type="main">Methods:Subjects with GERD were required to have oesophageal pH ≤ 4 for at least 10% of a 24-h recording. Effects of 20 mg rabeprazole on 24-h gastric and oesophageal pH were measured on days 1 and 7 of dosing. Integrated gastric and oesophageal acidity were calculated from time-weighted average hydrogen ion concentrations at each second of the 24-h record.<section xml:id="abs1-4"><title type="main">Results:At steady-state, 20 mg rabeprazole inhibited gastric acidity by 89% and oesophageal acidity by 95%. The first dose of rabeprazole inhibited gastric and oesophageal acidity by at least 70% of the steady-state effect. Oesophageal acidity could be divided into monophasic and biphasic patterns, and rabeprazole had different effects on oesophageal and gastric acidity in these two GERD subpopulations. The onset of action of the first dose of rabeprazole on gastric acidity was 4 h and on oesophageal acidity was 4 h in monophasic subjects and 7 h in biphasic subjects. Integrated acidity was more sensitive than time pH ≤ 4 in measuring the inhibitory actions of rabeprazole.<section xml:id="abs1-5"><title type="main">Conclusions:Integrated gastric and oesophageal acidity are quantitative measurements that provide useful and novel information regarding the pathophysiology of GERD as well as the impact of antisecretory agents such as rabeprazole. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| Perdomo, C. verfasserin aut Sloan, S. verfasserin aut Hahne, W. F. oth Barth, J. A. oth Rodriguez-Stanley, S. oth Robinson, M. oth In Alimentary pharmacology & therapeutics Oxford : Blackwell Science, 1987 16(2002), 3, Seite 0 Online-Ressource (DE-627)NLEJ243926529 (DE-600)2003094-0 1365-2036 nnns volume:16 year:2002 number:3 pages:0 http://dx.doi.org/10.1046/j.1365-2036.2002.01158.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 16 2002 3 0 |
| allfields_unstemmed |
10.1046/j.1365-2036.2002.01158.x doi (DE-627)NLEJ242206190 DE-627 ger DE-627 rakwb Gardner, J. D. verfasserin aut Integrated acidity and rabeprazole pharmacology Oxford UK Blackwell Science Ltd. 2002 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Integrated gastric and oesophageal acidity can be calculated from measurements of gastric and oesophageal pH and used to quantify gastric and oesophageal acidity over time. Rabeprazole is a new proton pump inhibitor that is effective in treating gastro-oesophageal reflux disease (GERD).<section xml:id="abs1-2"><title type="main">Aim:To use measurement of integrated gastric and oesophageal acidity to determine the onset, duration and overall effect of rabeprazole in subjects with GERD.<section xml:id="abs1-3"><title type="main">Methods:Subjects with GERD were required to have oesophageal pH ≤ 4 for at least 10% of a 24-h recording. Effects of 20 mg rabeprazole on 24-h gastric and oesophageal pH were measured on days 1 and 7 of dosing. Integrated gastric and oesophageal acidity were calculated from time-weighted average hydrogen ion concentrations at each second of the 24-h record.<section xml:id="abs1-4"><title type="main">Results:At steady-state, 20 mg rabeprazole inhibited gastric acidity by 89% and oesophageal acidity by 95%. The first dose of rabeprazole inhibited gastric and oesophageal acidity by at least 70% of the steady-state effect. Oesophageal acidity could be divided into monophasic and biphasic patterns, and rabeprazole had different effects on oesophageal and gastric acidity in these two GERD subpopulations. The onset of action of the first dose of rabeprazole on gastric acidity was 4 h and on oesophageal acidity was 4 h in monophasic subjects and 7 h in biphasic subjects. Integrated acidity was more sensitive than time pH ≤ 4 in measuring the inhibitory actions of rabeprazole.<section xml:id="abs1-5"><title type="main">Conclusions:Integrated gastric and oesophageal acidity are quantitative measurements that provide useful and novel information regarding the pathophysiology of GERD as well as the impact of antisecretory agents such as rabeprazole. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| Perdomo, C. verfasserin aut Sloan, S. verfasserin aut Hahne, W. F. oth Barth, J. A. oth Rodriguez-Stanley, S. oth Robinson, M. oth In Alimentary pharmacology & therapeutics Oxford : Blackwell Science, 1987 16(2002), 3, Seite 0 Online-Ressource (DE-627)NLEJ243926529 (DE-600)2003094-0 1365-2036 nnns volume:16 year:2002 number:3 pages:0 http://dx.doi.org/10.1046/j.1365-2036.2002.01158.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 16 2002 3 0 |
| allfieldsGer |
10.1046/j.1365-2036.2002.01158.x doi (DE-627)NLEJ242206190 DE-627 ger DE-627 rakwb Gardner, J. D. verfasserin aut Integrated acidity and rabeprazole pharmacology Oxford UK Blackwell Science Ltd. 2002 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Integrated gastric and oesophageal acidity can be calculated from measurements of gastric and oesophageal pH and used to quantify gastric and oesophageal acidity over time. Rabeprazole is a new proton pump inhibitor that is effective in treating gastro-oesophageal reflux disease (GERD).<section xml:id="abs1-2"><title type="main">Aim:To use measurement of integrated gastric and oesophageal acidity to determine the onset, duration and overall effect of rabeprazole in subjects with GERD.<section xml:id="abs1-3"><title type="main">Methods:Subjects with GERD were required to have oesophageal pH ≤ 4 for at least 10% of a 24-h recording. Effects of 20 mg rabeprazole on 24-h gastric and oesophageal pH were measured on days 1 and 7 of dosing. Integrated gastric and oesophageal acidity were calculated from time-weighted average hydrogen ion concentrations at each second of the 24-h record.<section xml:id="abs1-4"><title type="main">Results:At steady-state, 20 mg rabeprazole inhibited gastric acidity by 89% and oesophageal acidity by 95%. The first dose of rabeprazole inhibited gastric and oesophageal acidity by at least 70% of the steady-state effect. Oesophageal acidity could be divided into monophasic and biphasic patterns, and rabeprazole had different effects on oesophageal and gastric acidity in these two GERD subpopulations. The onset of action of the first dose of rabeprazole on gastric acidity was 4 h and on oesophageal acidity was 4 h in monophasic subjects and 7 h in biphasic subjects. Integrated acidity was more sensitive than time pH ≤ 4 in measuring the inhibitory actions of rabeprazole.<section xml:id="abs1-5"><title type="main">Conclusions:Integrated gastric and oesophageal acidity are quantitative measurements that provide useful and novel information regarding the pathophysiology of GERD as well as the impact of antisecretory agents such as rabeprazole. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| Perdomo, C. verfasserin aut Sloan, S. verfasserin aut Hahne, W. F. oth Barth, J. A. oth Rodriguez-Stanley, S. oth Robinson, M. oth In Alimentary pharmacology & therapeutics Oxford : Blackwell Science, 1987 16(2002), 3, Seite 0 Online-Ressource (DE-627)NLEJ243926529 (DE-600)2003094-0 1365-2036 nnns volume:16 year:2002 number:3 pages:0 http://dx.doi.org/10.1046/j.1365-2036.2002.01158.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 16 2002 3 0 |
| allfieldsSound |
10.1046/j.1365-2036.2002.01158.x doi (DE-627)NLEJ242206190 DE-627 ger DE-627 rakwb Gardner, J. D. verfasserin aut Integrated acidity and rabeprazole pharmacology Oxford UK Blackwell Science Ltd. 2002 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Integrated gastric and oesophageal acidity can be calculated from measurements of gastric and oesophageal pH and used to quantify gastric and oesophageal acidity over time. Rabeprazole is a new proton pump inhibitor that is effective in treating gastro-oesophageal reflux disease (GERD).<section xml:id="abs1-2"><title type="main">Aim:To use measurement of integrated gastric and oesophageal acidity to determine the onset, duration and overall effect of rabeprazole in subjects with GERD.<section xml:id="abs1-3"><title type="main">Methods:Subjects with GERD were required to have oesophageal pH ≤ 4 for at least 10% of a 24-h recording. Effects of 20 mg rabeprazole on 24-h gastric and oesophageal pH were measured on days 1 and 7 of dosing. Integrated gastric and oesophageal acidity were calculated from time-weighted average hydrogen ion concentrations at each second of the 24-h record.<section xml:id="abs1-4"><title type="main">Results:At steady-state, 20 mg rabeprazole inhibited gastric acidity by 89% and oesophageal acidity by 95%. The first dose of rabeprazole inhibited gastric and oesophageal acidity by at least 70% of the steady-state effect. Oesophageal acidity could be divided into monophasic and biphasic patterns, and rabeprazole had different effects on oesophageal and gastric acidity in these two GERD subpopulations. The onset of action of the first dose of rabeprazole on gastric acidity was 4 h and on oesophageal acidity was 4 h in monophasic subjects and 7 h in biphasic subjects. Integrated acidity was more sensitive than time pH ≤ 4 in measuring the inhibitory actions of rabeprazole.<section xml:id="abs1-5"><title type="main">Conclusions:Integrated gastric and oesophageal acidity are quantitative measurements that provide useful and novel information regarding the pathophysiology of GERD as well as the impact of antisecretory agents such as rabeprazole. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| Perdomo, C. verfasserin aut Sloan, S. verfasserin aut Hahne, W. F. oth Barth, J. A. oth Rodriguez-Stanley, S. oth Robinson, M. oth In Alimentary pharmacology & therapeutics Oxford : Blackwell Science, 1987 16(2002), 3, Seite 0 Online-Ressource (DE-627)NLEJ243926529 (DE-600)2003094-0 1365-2036 nnns volume:16 year:2002 number:3 pages:0 http://dx.doi.org/10.1046/j.1365-2036.2002.01158.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 16 2002 3 0 |
| source |
In Alimentary pharmacology & therapeutics 16(2002), 3, Seite 0 volume:16 year:2002 number:3 pages:0 |
| sourceStr |
In Alimentary pharmacology & therapeutics 16(2002), 3, Seite 0 volume:16 year:2002 number:3 pages:0 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Alimentary pharmacology & therapeutics |
| authorswithroles_txt_mv |
Gardner, J. D. @@aut@@ Perdomo, C. @@aut@@ Sloan, S. @@aut@@ Hahne, W. F. @@oth@@ Barth, J. A. @@oth@@ Rodriguez-Stanley, S. @@oth@@ Robinson, M. @@oth@@ |
| publishDateDaySort_date |
2002-01-01T00:00:00Z |
| hierarchy_top_id |
NLEJ243926529 |
| id |
NLEJ242206190 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242206190</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506180922.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2002 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1046/j.1365-2036.2002.01158.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242206190</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Gardner, J. D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Integrated acidity and rabeprazole pharmacology</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford UK</subfield><subfield code="b">Blackwell Science Ltd.</subfield><subfield code="c">2002</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Integrated gastric and oesophageal acidity can be calculated from measurements of gastric and oesophageal pH and used to quantify gastric and oesophageal acidity over time. Rabeprazole is a new proton pump inhibitor that is effective in treating gastro-oesophageal reflux disease (GERD).<section xml:id="abs1-2"><title type="main">Aim:To use measurement of integrated gastric and oesophageal acidity to determine the onset, duration and overall effect of rabeprazole in subjects with GERD.<section xml:id="abs1-3"><title type="main">Methods:Subjects with GERD were required to have oesophageal pH ≤ 4 for at least 10% of a 24-h recording. Effects of 20 mg rabeprazole on 24-h gastric and oesophageal pH were measured on days 1 and 7 of dosing. Integrated gastric and oesophageal acidity were calculated from time-weighted average hydrogen ion concentrations at each second of the 24-h record.<section xml:id="abs1-4"><title type="main">Results:At steady-state, 20 mg rabeprazole inhibited gastric acidity by 89% and oesophageal acidity by 95%. The first dose of rabeprazole inhibited gastric and oesophageal acidity by at least 70% of the steady-state effect. Oesophageal acidity could be divided into monophasic and biphasic patterns, and rabeprazole had different effects on oesophageal and gastric acidity in these two GERD subpopulations. The onset of action of the first dose of rabeprazole on gastric acidity was 4 h and on oesophageal acidity was 4 h in monophasic subjects and 7 h in biphasic subjects. Integrated acidity was more sensitive than time pH ≤ 4 in measuring the inhibitory actions of rabeprazole.<section xml:id="abs1-5"><title type="main">Conclusions:Integrated gastric and oesophageal acidity are quantitative measurements that provide useful and novel information regarding the pathophysiology of GERD as well as the impact of antisecretory agents such as rabeprazole.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2002</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2002||||||||||</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Perdomo, C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sloan, S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hahne, W. F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Barth, J. A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rodriguez-Stanley, S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Robinson, M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Alimentary pharmacology & therapeutics</subfield><subfield code="d">Oxford : Blackwell Science, 1987</subfield><subfield code="g">16(2002), 3, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243926529</subfield><subfield code="w">(DE-600)2003094-0</subfield><subfield code="x">1365-2036</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:16</subfield><subfield code="g">year:2002</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1046/j.1365-2036.2002.01158.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">16</subfield><subfield code="j">2002</subfield><subfield code="e">3</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| series2 |
Blackwell Publishing Journal Backfiles 1879-2005 |
| author |
Gardner, J. D. |
| spellingShingle |
Gardner, J. D. Integrated acidity and rabeprazole pharmacology |
| authorStr |
Gardner, J. D. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ243926529 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
NL |
| publishPlace |
Oxford UK |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1365-2036 |
| topic_title |
Integrated acidity and rabeprazole pharmacology |
| publisher |
Blackwell Science Ltd. |
| publisherStr |
Blackwell Science Ltd. |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
w f h wf wfh j a b ja jab s r s srs m r mr |
| hierarchy_parent_title |
Alimentary pharmacology & therapeutics |
| hierarchy_parent_id |
NLEJ243926529 |
| hierarchy_top_title |
Alimentary pharmacology & therapeutics |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ243926529 (DE-600)2003094-0 |
| title |
Integrated acidity and rabeprazole pharmacology |
| ctrlnum |
(DE-627)NLEJ242206190 |
| title_full |
Integrated acidity and rabeprazole pharmacology |
| author_sort |
Gardner, J. D. |
| journal |
Alimentary pharmacology & therapeutics |
| journalStr |
Alimentary pharmacology & therapeutics |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2002 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Gardner, J. D. Perdomo, C. Sloan, S. |
| container_volume |
16 |
| physical |
Online-Ressource |
| format_se |
Elektronische Aufsätze |
| author-letter |
Gardner, J. D. |
| doi_str_mv |
10.1046/j.1365-2036.2002.01158.x |
| author2-role |
verfasserin |
| title_sort |
integrated acidity and rabeprazole pharmacology |
| title_auth |
Integrated acidity and rabeprazole pharmacology |
| abstract |
Integrated gastric and oesophageal acidity can be calculated from measurements of gastric and oesophageal pH and used to quantify gastric and oesophageal acidity over time. Rabeprazole is a new proton pump inhibitor that is effective in treating gastro-oesophageal reflux disease (GERD).<section xml:id="abs1-2"><title type="main">Aim:To use measurement of integrated gastric and oesophageal acidity to determine the onset, duration and overall effect of rabeprazole in subjects with GERD.<section xml:id="abs1-3"><title type="main">Methods:Subjects with GERD were required to have oesophageal pH ≤ 4 for at least 10% of a 24-h recording. Effects of 20 mg rabeprazole on 24-h gastric and oesophageal pH were measured on days 1 and 7 of dosing. Integrated gastric and oesophageal acidity were calculated from time-weighted average hydrogen ion concentrations at each second of the 24-h record.<section xml:id="abs1-4"><title type="main">Results:At steady-state, 20 mg rabeprazole inhibited gastric acidity by 89% and oesophageal acidity by 95%. The first dose of rabeprazole inhibited gastric and oesophageal acidity by at least 70% of the steady-state effect. Oesophageal acidity could be divided into monophasic and biphasic patterns, and rabeprazole had different effects on oesophageal and gastric acidity in these two GERD subpopulations. The onset of action of the first dose of rabeprazole on gastric acidity was 4 h and on oesophageal acidity was 4 h in monophasic subjects and 7 h in biphasic subjects. Integrated acidity was more sensitive than time pH ≤ 4 in measuring the inhibitory actions of rabeprazole.<section xml:id="abs1-5"><title type="main">Conclusions:Integrated gastric and oesophageal acidity are quantitative measurements that provide useful and novel information regarding the pathophysiology of GERD as well as the impact of antisecretory agents such as rabeprazole. |
| abstractGer |
Integrated gastric and oesophageal acidity can be calculated from measurements of gastric and oesophageal pH and used to quantify gastric and oesophageal acidity over time. Rabeprazole is a new proton pump inhibitor that is effective in treating gastro-oesophageal reflux disease (GERD).<section xml:id="abs1-2"><title type="main">Aim:To use measurement of integrated gastric and oesophageal acidity to determine the onset, duration and overall effect of rabeprazole in subjects with GERD.<section xml:id="abs1-3"><title type="main">Methods:Subjects with GERD were required to have oesophageal pH ≤ 4 for at least 10% of a 24-h recording. Effects of 20 mg rabeprazole on 24-h gastric and oesophageal pH were measured on days 1 and 7 of dosing. Integrated gastric and oesophageal acidity were calculated from time-weighted average hydrogen ion concentrations at each second of the 24-h record.<section xml:id="abs1-4"><title type="main">Results:At steady-state, 20 mg rabeprazole inhibited gastric acidity by 89% and oesophageal acidity by 95%. The first dose of rabeprazole inhibited gastric and oesophageal acidity by at least 70% of the steady-state effect. Oesophageal acidity could be divided into monophasic and biphasic patterns, and rabeprazole had different effects on oesophageal and gastric acidity in these two GERD subpopulations. The onset of action of the first dose of rabeprazole on gastric acidity was 4 h and on oesophageal acidity was 4 h in monophasic subjects and 7 h in biphasic subjects. Integrated acidity was more sensitive than time pH ≤ 4 in measuring the inhibitory actions of rabeprazole.<section xml:id="abs1-5"><title type="main">Conclusions:Integrated gastric and oesophageal acidity are quantitative measurements that provide useful and novel information regarding the pathophysiology of GERD as well as the impact of antisecretory agents such as rabeprazole. |
| abstract_unstemmed |
Integrated gastric and oesophageal acidity can be calculated from measurements of gastric and oesophageal pH and used to quantify gastric and oesophageal acidity over time. Rabeprazole is a new proton pump inhibitor that is effective in treating gastro-oesophageal reflux disease (GERD).<section xml:id="abs1-2"><title type="main">Aim:To use measurement of integrated gastric and oesophageal acidity to determine the onset, duration and overall effect of rabeprazole in subjects with GERD.<section xml:id="abs1-3"><title type="main">Methods:Subjects with GERD were required to have oesophageal pH ≤ 4 for at least 10% of a 24-h recording. Effects of 20 mg rabeprazole on 24-h gastric and oesophageal pH were measured on days 1 and 7 of dosing. Integrated gastric and oesophageal acidity were calculated from time-weighted average hydrogen ion concentrations at each second of the 24-h record.<section xml:id="abs1-4"><title type="main">Results:At steady-state, 20 mg rabeprazole inhibited gastric acidity by 89% and oesophageal acidity by 95%. The first dose of rabeprazole inhibited gastric and oesophageal acidity by at least 70% of the steady-state effect. Oesophageal acidity could be divided into monophasic and biphasic patterns, and rabeprazole had different effects on oesophageal and gastric acidity in these two GERD subpopulations. The onset of action of the first dose of rabeprazole on gastric acidity was 4 h and on oesophageal acidity was 4 h in monophasic subjects and 7 h in biphasic subjects. Integrated acidity was more sensitive than time pH ≤ 4 in measuring the inhibitory actions of rabeprazole.<section xml:id="abs1-5"><title type="main">Conclusions:Integrated gastric and oesophageal acidity are quantitative measurements that provide useful and novel information regarding the pathophysiology of GERD as well as the impact of antisecretory agents such as rabeprazole. |
| collection_details |
GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE |
| container_issue |
3 |
| title_short |
Integrated acidity and rabeprazole pharmacology |
| url |
http://dx.doi.org/10.1046/j.1365-2036.2002.01158.x |
| remote_bool |
true |
| author2 |
Perdomo, C. Sloan, S. Hahne, W. F. Barth, J. A. Rodriguez-Stanley, S. Robinson, M. |
| author2Str |
Perdomo, C. Sloan, S. Hahne, W. F. Barth, J. A. Rodriguez-Stanley, S. Robinson, M. |
| ppnlink |
NLEJ243926529 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth |
| doi_str |
10.1046/j.1365-2036.2002.01158.x |
| up_date |
2024-07-06T01:12:50.973Z |
| _version_ |
1803790184323481600 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242206190</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506180922.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2002 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1046/j.1365-2036.2002.01158.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242206190</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Gardner, J. D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Integrated acidity and rabeprazole pharmacology</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford UK</subfield><subfield code="b">Blackwell Science Ltd.</subfield><subfield code="c">2002</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Integrated gastric and oesophageal acidity can be calculated from measurements of gastric and oesophageal pH and used to quantify gastric and oesophageal acidity over time. Rabeprazole is a new proton pump inhibitor that is effective in treating gastro-oesophageal reflux disease (GERD).<section xml:id="abs1-2"><title type="main">Aim:To use measurement of integrated gastric and oesophageal acidity to determine the onset, duration and overall effect of rabeprazole in subjects with GERD.<section xml:id="abs1-3"><title type="main">Methods:Subjects with GERD were required to have oesophageal pH ≤ 4 for at least 10% of a 24-h recording. Effects of 20 mg rabeprazole on 24-h gastric and oesophageal pH were measured on days 1 and 7 of dosing. Integrated gastric and oesophageal acidity were calculated from time-weighted average hydrogen ion concentrations at each second of the 24-h record.<section xml:id="abs1-4"><title type="main">Results:At steady-state, 20 mg rabeprazole inhibited gastric acidity by 89% and oesophageal acidity by 95%. The first dose of rabeprazole inhibited gastric and oesophageal acidity by at least 70% of the steady-state effect. Oesophageal acidity could be divided into monophasic and biphasic patterns, and rabeprazole had different effects on oesophageal and gastric acidity in these two GERD subpopulations. The onset of action of the first dose of rabeprazole on gastric acidity was 4 h and on oesophageal acidity was 4 h in monophasic subjects and 7 h in biphasic subjects. Integrated acidity was more sensitive than time pH ≤ 4 in measuring the inhibitory actions of rabeprazole.<section xml:id="abs1-5"><title type="main">Conclusions:Integrated gastric and oesophageal acidity are quantitative measurements that provide useful and novel information regarding the pathophysiology of GERD as well as the impact of antisecretory agents such as rabeprazole.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2002</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2002||||||||||</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Perdomo, C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sloan, S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hahne, W. F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Barth, J. A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rodriguez-Stanley, S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Robinson, M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Alimentary pharmacology & therapeutics</subfield><subfield code="d">Oxford : Blackwell Science, 1987</subfield><subfield code="g">16(2002), 3, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243926529</subfield><subfield code="w">(DE-600)2003094-0</subfield><subfield code="x">1365-2036</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:16</subfield><subfield code="g">year:2002</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1046/j.1365-2036.2002.01158.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">16</subfield><subfield code="j">2002</subfield><subfield code="e">3</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.4020357 |